Viewing Study NCT06282692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:44 PM
Ignite Modification Date: 2026-02-03 @ 3:38 AM
Study NCT ID: NCT06282692
Status: RECRUITING
Last Update Posted: 2024-02-28
First Post: 2023-06-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
Sponsor: Dr. Soetomo General Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None COVID-19 Pandemic View
None COVID-19 Vaccines View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Inactivated COVID-1 9 Vaccine View
None Immunogenicity View
None Safety View
None COVID-19 View
None Indonesia View
None Immunobridging Study View